X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The non-exclusive license grants Adimab rights to implement select strains of AlivaMab Mouse into its proprietary yeast-based technology for antibody drug discovery for its clients.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Adimab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 09, 2023
Details:
New strains of AlivaMab XKL Mice offered by Ablexis that further expand the molecular and epitope diversity of the immune response to promote even broader responses against the increasingly complex types of antigens at the cutting edge of antibody drug discovery.
Lead Product(s): Antibody-based Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: AlivaMab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The companies together have generated and recovered sequences encoding a rich panel of human antibodies against the S1 spike protein of the SARS-CoV-2 virus.
Lead Product(s): SARS-CoV-2 S1 antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Berkeley Lights
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
